Wells Fargo maintains Buy rating on Elevance Health (ELV) with unchanged price target.

Elevance Health, Inc. (NYSE: ELV) is listed as one of the 11 Best 52-Week Low Stocks to Buy Right Now. Wells Fargo analyst Stephen Baxter maintained a Buy rating on ELV with a price target of $478 after the company exceeded analyst expectations in the fiscal first quarter of 2025.

Elevance Health, Inc. (NYSE: ELV) reported an operating revenue of $48.8 billion, up 15.4% from Q1 2024, and an EPS of $11.97, surpassing analyst targets. Medical Members grew to 45.8 million, driven by expansion and retention in Medicare Advantage, while Individual ACA membership is expected to slow in Q2.

Elevance Health, Inc. (NYSE: ELV) is a major health insurer in the U.S., focusing on integrated, whole-health approaches for individuals and communities. The company aims to improve health by addressing physical, behavioral, and social needs through their digital solutions.

While Elevance Health (ELV) shows promise as an investment, there are AI stocks with greater upside potential and lower risk. For those seeking an undervalued AI stock benefiting from tariffs and the onshoring trend, explore more in the free report on the best short-term AI stock.

Read more at Yahoo Finance: Wells Fargo Maintained a Buy Rating on Elevance Health (ELV), Kept the PT Unchanged